Considering the terminal half-life [t1⁄2: ~ 6.3 days] of humanized anti-RON ADCs in mice [1–6] and the tumor regrowth curve, we calculated tumoristatic concentrations [TSCs, the minimal concentrations required to balance tumor growth and inhibition]. The gene discussed is MST1R; the disease is neoplasm.